Clathrin and caveolins are known for their involvement in the internalization of numerous receptors. Here we show that in polarized epithelial Madin-Darby canine kidney cells, both the clathrin machinery and caveolins are involved in the endocytosis and delivery to the plasma membrane (PM) of the M1 muscarinic acetylcholine receptor (mAChR). We initially localized this receptor to the lateral membrane, where it accumulates proximal to the tight junctions. From there it is internalized through the clathrin-mediated pathway. In addition, the receptor may associate on the PM with caveolin (cav) 2 or in intracellular compartments with either cav 2, or monomeric or oligomeric cav 1. Association of the PM M1 mAChR with cav 2 inhibits receptor endocytosis through the clathrin-mediated pathway or retains the receptor in an intracellular compartment. This intracellular association attenuates receptor trafficking. Expression of cav 1 with cav 2 rescues the latter's inhibitory effect. The caveolins stimulate M1 mAChR oligomerization thus maintaining a constant amount of monomeric receptor. These results provide evidence that caveolins play a role in the attenuation of the M1 muscarinic receptor's intracellular trafficking to and from the PM.
INTRODUCTION
Endocytosis and the events leading up to it are of prime importance as they enable cells to regulate receptor-dependent signaling pathways as well as a variety of cellular functions. Clathrin-mediated endocytosis (CME) is the most well-characterized pathway for the internalization of soluble macromolecules and integral membrane proteins from the plasma membrane (PM; Conner and Schmid, 2003) . G-protein-coupled receptors (GPCRs), being the largest receptor group, resort to a unique set of events that couple signaling and endocytosis (von Zastrow, 2003) . Within the GPCRs, the muscarinic acetylcholine receptors (mAChRs) mediate the acetylcholine-dependent stimulus and are, therefore, highly regulated by G-protein activation and receptor endocytosis. In mammals, five distinct mAChR subtypes (M1-M5) exist. The M1, M3, and M5 mAChRs are coupled to the G␣q/11 and G␣q13 G proteins, leading to, for example, activation of phospholipase C (PLC) and phospholipase D (PLD), which have been shown to affect endocytosis (Shen et al., 2001 ); M2 and M4 mAChRs activate Gi proteins, leading to the inhibition of adenylyl cyclase (van Koppen and Kaiser, 2003) . The different mAChR subtypes display unique, but not exclusive, expression patterns in the CNS and peripheral organs, such as the heart, epithelial exocrine glands, and smooth muscle tissue (Matsui et al., 2004) . Activation of mAChRs has been found to elicit pigment-granule dispersion in retinal pigment epithelium, which is blocked by antagonist specific to M1 and M3 mAChRs (Phatarpekar et al., 2005) . A study performed on human conjunctival epithelium revealed the expression of all five mAChRs. Specifically, M1 mAChRs were detected only intracellularly, but were mobilized to the PM when cholera toxin and hydrocortisone were omitted from the culture medium (Enriquez de Salamanca et al., 2005) . Recent transcriptome analysis has shown that M1 mAChRs are expressed in epithelial cells to a degree similar to that appearing in the nervous system (see CHRM1 in GeneCards: www.genecards.org and Su et al., 2004) with transcriptome analysis at Gene Expression Omnibus (http:// www.ncbi.nlm.nih.gov/projects/geo/index.cgi). In addition, M1 mAChR-deficient mice show a stronger response to amphetamines (van Koppen and Kaiser, 2003) .
Prolonged exposure of mAChRs, as well as other GPCRs, to agonists typically results in the attenuation of their cellular responses and induces their sequestration in internal organelles. This sequestration may represent endocytosis of receptors via clathrin-coated vesicles (von Zastrow et al., 1993; Tolbert and Lameh, 1996) or caveolae (Roettger et al., 1995; Henley et al., 1998; Dessy et al., 2000; Lamb et al., 2002; McFarland et al., 2004) , or it may be associated with conformational changes of the receptor in the PM that make it inaccessible to agonists (Roettger et al., 1995) . Endocytosis may play different roles for different GPCRs. For example, ␤2-adrenergic receptor is endocytosed and recycled back to the PM, where it is resensitized. The receptor is internalized by early-recycling-sorting endosomes, from which it is returned to the PM (Pitcher et al., 1995) . Internalization may also prolong desensitization of the M4 mAChR (Bogatkewitsch et al., 1996; Lee et al., 1998; Vogler et al., 1998) .
Many reports have shown the uncoupling of GPCR downregulation and endocytosis. Specifically, deletion of a large portion of the third cytoplasmic loop of the M1 mAChRs strongly reduces agonist-induced M1 down-regulation without affecting receptor internalization in Y1 adrenal carcinoma cells. In JEG-3 cells, M1 mAChR undergoes agonistinduced down-regulation, but not internalization. Several substitution mutants of M1 mAChRs stably transfected in CHO cells are defective in down-regulation, but not agonistinduced receptor internalization (Shockley et al., 1997) . Thus, endocytosis appears to be segregated from the degradation process of the M1 receptor. The mechanism by which GPCRs, and specifically mAChRs, internalize has recently been the focus of a great deal of research, and the mechanism of internalization, CME or caveolae, appears to be dependent on the cell line under study (Silva et al., 1986; Slowiejko et al., 1996; Tolbert and Lameh, 1996; Feron et al., 1997; Dessy et al., 2000; Roseberry and Hosey, 2001) .
Caveolae-dependent internalization of sphingolipids and sphingolipid-binding toxins (cholera toxin and shiga toxin), GPI-anchored proteins, the autocrine motility factor (AMF), endothelin, growth hormone, IL2 receptors, viruses [including simian virus (SV) 40], and bacteria has been well documented (Lamaze et al., 2001; Le et al., 2002; Pelkmans and Helenius, 2002; Conner and Schmid, 2003; Nabi and Le, 2003) .
The caveolin proteins are the major constituents of cellsurface caveolae, a specialized form of detergent-resistant membranes (DRMs). Mammals express three isoforms, of which caveolin (cav) 1 and 3 are predominantly localized at the cell surface (Parton, 2003) . Generally, cav 2 is colocalized with Golgi markers, unless targeted to the PM by oligomerization with cav 1 (Parolini et al., 1999) . Caveolins localized to the Golgi are mainly in the nonnumeric state and are detergent-soluble (Pol et al., 2005) . Caveolins, and specifically cav 1, have been extensively studied in polarized epithelial Madin-Darby canine kidney (MDCK) cells and localized to both apical and basolateral PM and Golgi (Kurzchalia et al., 1992; Dupree et al., 1993; Sargiacomo et al., 1993; Parton, 1994; Parton et al., 1994; Hailstones et al., 1998; Vogel et al., 1998) . Expression of cav 1 causes the formation of caveolae and a lack of cav 1 or 3 results in loss of caveolae (Fra et al., 1995; Vogel et al., 1998) . In polarized MDCK cells, cav 1 and 2 are found as hetero-oligomers on basolateral (BL) caveolae, whereas the apical (AP) membrane, where only cav 1 is present, lacks these caveolae (Scheiffele et al., 1998; Vogel et al., 1998; Lahtinen et al., 2003) . Cross-linking of apical raft proteins by primary and secondary antibodies resulted in cav 1 recruitment to the cluster followed by caveolae internalization (Verkade et al., 2000) . Expression of a cav 1 or 2 mutant prevents the formation of cav 1-2 hetero-oligomeric complexes and leads to intracellular retention of cav 2 and the disappearance of caveolae from the BL membrane (Dupree et al., 1993; Scheiffele et al., 1998; Vogel et al., 1998) . Expression of cav 2 results in its enrichment in BL internal vesicles. A study on epithelial FRT cells lacking both caveolins clearly shows that cav 2 is preferentially localized to the Golgi, whereas cav 1 is preferentially found at the PM (Mora et al., 1999) . Cav 1 has also been suggested to associate with bone morphogenetic protein (BMP) receptors on the PM. Binding receptor type-I (BRIa) associates with and shuttles between cav 1␣ and ␤, depending on the presence of the BMP-2 ligand. In addition, the cav 1␤ isoform inhibits BMP signaling, whereas the ␣ isoform does not (Nohe et al., 2005) .
Clearly, the events that precede endocytosis and the mechanism by which GPCRs, and specifically mAChRs, are endocytosed are of prime interest, as this is the main mechanism for the attenuation of receptor signaling. Here we show that the M1 mAChR is localized to the lateral PM, proximal to the tight-junction complex, and internalized by the clathrin-dependent-endocytosis system. We also provide preliminary evidence for cav 2 inhibition of receptor arrival at the PM and internalization, a phenomenon that may be abolished by cav 1.
MATERIALS AND METHODS

Materials
Chemicals and anti-Flag antibody were purchased from Sigma-Aldrich (Rehovot, Israel), unless otherwise specified. Growth media were purchased from Biological Industries (Beit Haemek, Israel). All fluorescent secondary antibodies and Alexa 594-transferrin were purchased from Molecular Probes (Eugene, OR). MG132 stock solution (20 mM in DMSO) was obtained from Calbiochem (San Diego, CA), X22 antibody against clathrin heavy chain was kindly provided by Frances Brodsky (UCSF, San Francisco, CA). Rat mAb against ZO-1 was obtained from Chemicon International (Temecula, CA) and GP135 was a kind gift from George Ojakian (SUNY, Brooklyn). Anti-caveolin 1 (clone pAb) and caveolin 2 (clone 65) were obtained from Transduction Laboratories (Lexington, KY), anti-cav 2, 12CA5 and 9E10 and mouse antiubiquitin (P4G7) antibodies were purchased from Covance (Berkeley CA), and anti-E-cadherin was obtained from Zymed (San Francisco, CA). M1 mAChR cDNA was obtained from UMR cDNA Resource Center (University of Missouri-Rolla, Rolla, MO). pDsRed2-Rab5a/7/9/11 (BD Biosciences Clontech, Palo Alto, CA) was kindly provided by Rick Pagano (Rochester, MN; Choudhury et al., 2005) . All images were compiled using the Adobe Photoshop (San Jose, CA), and/or Canvas software (ACD Systems International, Saanichton, British Columbia, Canada) and are representative of the original data.
Methods
DNA Constructs and Cloning. The M1 mAChR cDNA fused to triple hemagglutin (HA) at the N-terminal was obtained from the UMR cDNA Resource Center, (www. cdna.org). The cDNA was amplified using the following primers (5Ј primer: ACC ACG CAA GCT TAC CAT GTA CCC ATA CGA TGT TCC AGA TTA CG and 3Ј primer: ACC ACG CGG ATC CGC GCA TTG GCG GGA GGG AGT GCG GTG CAC G), followed by digestion with HindIII and BamHI, and cloned at the N-terminal of green fluorescent protein (GFP) in pCB7-GFP to obtain extracellular triple HA and C-terminal intracellular GFP. The construct was transfected into MDCK tet off cells (T23) and selected using hygromycin to produce stable MDCK T23 M1 mAChR. Adenoviral Expression, Immunofluorescence, and Biochemical Assays. MDCK cells were grown as previously described (Altschuler et al., 1999) . Recombinant tetracycline-regulated adenovirus-expressing dominant dynamin I K44A, dominant-negative clathrin hub, and the wild-type form of cav 1 and 2 were produced and used as described previously (Altschuler et al., 1998 (Altschuler et al., , 1999 . The protein levels were regulated by the concentration of doxycycline (Dx), the amount of virus, and the length of time after infection and/or Dx removal, to obtain the minimal expression that results in an inhibitory or stimulatory effect on endocytosis and avoids toxic repercussions. Cells infected by recombinant adenovirus were incubated for 16 -18 h to express recombinant proteins, except for the clathrin hub, which required 24 -26-h incubation. We routinely used 60 -90 pfu/cell to obtain the minimal functional effect. These conditions minimized the possibility of toxic effects and produced an adequate signal for our localization and functional studies. Controls in all of the experiments included cells that were 1) not infected, 2) infected but whose expression was fully repressed by 20 ng/ml Dx, or 3) infected with a control virus encoding ␤-galactosidase to identify possible viral effects. In all cases, Dx treatment resulted in the loss of any effect on endocytosis or redistribution of the M1 mAChRs. In biochemical or immunofluorescence experiments including carbachol, its concentration was 1 mM for the indicated periods. Images were taken using a Nikon TE-2000S (Melville, NY) inverted fluorescence microscope with a plan Apo 60ϫ objective lens (Nikon), equipped with a Z stepper and a Hamamatsu CCD ORCAII camera (Tucson, AZ). All images were deconvolved with SimplePCI software (Improvision, Coventry, United Kingdom). Endocytosis was performed according to loss-of-surface protocols. In brief, MDCK control cells and those expressing M1 mAChR were incubated with or without 1 mM carbachol for the indicated time periods, followed by rapid cooling of the cells. Subse-quently, the receptor remaining on the PM was measured by the binding of iodinated anti-HA-12CA5 antibody to M1 mAChR on the BL PM. To calculate the amount of internalized M1 mAChR, the radioactivity bound to MDCK not expressing M1 mAChR was subtracted from the radioactivity bound to cells expressing M1 mAChR. Subsequently, the radioactivity associated with cells treated with carbachol was subtracted from the radioactivity of the untreated cells (Total Bound), yielding the amount of radioactivity representing internalized M1 mAChR. The radioactivity of the cells expressing M1 was in the range of 60,000 -100,000 cpm per sample. The background was generally between 1 and 2% of the experimental total bound radioactivity and represented the nonspecific 12CA5 bound to cells not expressing the M1 mAChR. To obtain immunofluorescent transferrin or E-cadherin, the following experiment was conducted: briefly, MDCK cells were grown in Corning transwells (Corning Glassworks, Corning, NY) for 3 d, infected with the appropriate recombinant adenoviruses, and incubated for 18 h. The cells were then rinsed with ice-cold phosphate-buffered saline (PBS; containing 1 mM CaCl 2 and 1 mM MgCl 2 ), and then incubated with 40 l of media containing Alexa 594-transferrin or anti-E-cadherin for 60 min at 4°C. Excess transferrin or E-cadherin antibody was removed by extensive washes. The bound antibody was fixed with paraformaldehyde (PFA) according to an immunofluorescence protocol (Altschuler et al., 1999) .
Equilibrium Flotations. Flotation of detergent-insoluble complexes was performed as described previously (Rouvinski et al., 2003) . In brief, MDCK cells, cultured for 3 d on 90-mm dishes (1 ϫ 10 7 cells), were gently scraped, pelleted, and lysed with 550 l of flotation lysis buffer (1% vol/vol Triton X-100 in TNE [150 mM NaCl, 25 mM Tris-HCl, 5 mM EDTA, pH 7.5]) on ice for 30 min. The lysates were spun at low speed (3000 rpm, 4°C, 5 min) in an Eppendorf centrifuge (Fremont, CA; 5417; g av ϭ 960 ϫ g) to generate a postnuclear supernatant (PNS). All subsequent steps were performed on ice. The lysates were adjusted to 35% (vol/vol) Nycodenz by adding an equal volume of ice-cold 70% Nycodenz dissolved in TNE. Each sample (900 ml) was loaded at the bottom of a TLS-55 tube (Beckman Instruments, Fullerton, CA). An 8 -25% Nycodenz linear-step gradient in TNE was then laid above the lysate (200 l each of 25, 22.5, 20, 18, 15, 12, and 8% Nycodenz) . The tubes were spun at 55,000 rpm for 3 h, at 4°C in a TLS-55 rotor (g av ϭ 200,000 ϫ g). Twelve 180-l fractions were collected from the top of the tube. The buoyant material migrated to low-density fractions 1-7.
Coimmunoprecipitation. Immunoprecipitation of the M1 mAChR was performed according to Lu et al. (2001) . In brief, MDCK-M1 mAChR cells were infected with different caveolin adenoviruses followed by incubation for 18 h to allow expression. Subsequently, cells were scraped and lysed in 1 ml of RIPA buffer containing 50 mM Tris (pH 7.4), 135 mM NaCl, 1% TX-100, and 60 mM octylglucoside and supplemented with protease inhibitors (2 mM phenylmethylsulfonyl fluoride and 100 U/ml aprotinin) and 2 mM sodium orthovanadate, 10 mM sodium pyrophosphate, and 20 mM NaF. Lysates were cleared by centrifugation at 12,000 ϫ g for 30 min at 4°C, and 20-l aliquots were saved as total protein lysates for analyses. Supernatants were incubated with anti-HA antibody (12CA5, 1 g) and protein A-Sepharose beads (20 l packed beads) at 4°C for 90 min rocking. At the end of the incubation, beads were washed five times with RIPA lysis buffer. The resulting immunoprecipitated immunocomplexes were solubilized in 35 l of high-pH sample buffer, resolved by SDS-PAGE, and transferred to a nitrocellulose membrane. The protein complex was detected by Western blot analysis and developed by ECL (Amersham Pharmacia Biotech, Piscataway, NJ).
Transient Transfection of RFP-Rab cDNAs. Full-length wild-type Rab cDNAs (Rab5a, Rab11, Rab7, and Rab9) cloned into pDsRed2 were transiently transfected into MDCK-M1 mAChR cells using Metafecten Pro (Biontex, Martinsried/Planegg, Germany) according to the manufacturer's protocol at a ratio of 1 g DNA to 3 l metafecten for 4 ϫ 10 5 MDCK cells. At this ratio we obtained 20 -30% transfected cells and the endosome sizes were similar to those obtained with antibody to other endosomal markers such as EEA1.
RESULTS
To investigate the mechanism underlying M1 mAChR endocytosis and membrane traffic, we subcloned the gene encoding the receptor as a fusion with GFP to generate an in-frame fusion protein in which GFP is fused to the C terminus of M1 mAChR (see Materials and Methods) . This construct places GFP after the C-terminal tail in the cytoplasmic environment. Thus, the GFP does not interfere with ligand binding or with the conformational changes that follow receptor activation. We then generated a stable cell line that modestly expresses the receptor.
M1 Muscarinic Receptor Localizes to the Basolateral Plasma Membrane in MDCK Cells
To identify the subcellular epithelial structure to which M1 mAChR is localized, we performed immunofluorescence colocalization experiments with markers for the AP PM, tight junction and BL PM. Figure 1A shows an AP section decorated with the AP marker gp135 and the absence of GFP-M1 mAChR staining. A BL section, taken 4 m below, shows the absence of gp135 and clear classic BL PM localization of the M1 mAChR. In Figure 1B , two sections taken at the level of the tight junction clearly show the ZO1 tight-junction marker. Both sections, taken 1 m apart, reveal M1 mAChR. Note that the lower section is sharper, indicating that the receptor is localized in the BL region of the tight junction. In Figure 1C , the M1 mAChR is completely colocalized with the transferrin bound to the BL-resident PM transferrin receptor. Moreover, the M1 mAChR is concentrated in punctate staining on the lateral membrane and is not evenly dispersed, indicative of the receptor's localization in a specific structure, such as clathrin-coated pits, rafts, or caveolae. To confirm the observed uneven distribution of M1 mAChR along the BL PM, we colocalized the receptor with E-cadherin, the latter known to be distributed evenly along the lateral membrane. Four lateral sections beginning 1 m under the tight junction and spaced 2 m apart are shown in Figure 2 . The M1 mAChR is differentially distributed on the lateral membrane and mainly concentrated proximal to the tight junction. Its distribution declines as we proceed away from the tight junction, down the lateral membrane. We concluded that M1 mAChR is unevenly localized through the lateral PM, its highest concentration near the tight junction.
Rapid Endocytosis of the M1 Muscarinic Receptor
To gain an understanding of M1 mAChR endocytosis, we utilized both biochemical and microscopic approaches. In the steady state, the M1 mAChR appeared to be on the lateral PM with only a modest amount of it internalized ( Figure 1 , B and C). Therefore, we treated the cells with the well-known muscarinic agonist carbachol at the saturating concentration of 1 mM and incubated them for different periods of time at 37°C. At the indicated time points, the cells were rapidly cooled and processed for microscopy or biochemical quantitation of endocytosed M1 mAChR. For the biochemical assay, we resorted to the loss-of-surface approach, in which the amount of receptor remaining on the surface at the indicated time points after agonist stimulation is quantitated. For quantitation, we iodinated a 12CA5 antibody. After treatment with or without carbachol, the cells were rapidly cooled and bound the iodinated 12CA5 antibody, on the BL PM, by means of the HA tag subcloned into the N-terminal extracellular domain of the receptor. In Figure 3A , very rapid internalization was seen in the first 2 min after agonist treatment. This rate accounted for ϳ15% of the total receptor bound per minute. Within 5 min of carbachol treatment, the internalization rate had declined dramatically, to ϳ3% per minute. We reasoned that the drop in internalization rate might be due to rapid recycling of the M1 mAChR returning to the BL PM.
To image carbachol-dependent endocytosis of M1 mAChR, cells treated with carbachol for the indicated periods of time were cooled and fixed with PFA, followed by immunocytochemistry. In Figure 3B , we show a lateral section proximal to the tight junction where both PM and endocytosed M1 mAChR are observed at maximum intensity. The steady-state distribution of M1 mAChR, shown in Figures 1, B and C, 2, and 3B (0 time), indicates that ϳ10 -15% (as quantitated by ImageJ densitometry) of the total amount of receptor is in internal endosomal compartments, whereas most of it is concentrated on the lateral membrane. Constitutive agonist treatment (1 mM carbachol) resulted in rapid endocytosis: within 15 min, with about half of the receptor internalized. Within 30 min, most of it was internalized. Staining of the membrane by the receptor was minimal and unchanged from the 30-min time point through 45 and 60 min. In contrast to the microscopy-based assay, the biochemical assay showed a plateau at ϳ40 -50% of the internalized receptors. This difference may be explained by the higher sensitivity of the iodinated antibody tracer or difficulty in detecting the recycling M1 mAChR. Nevertheless, the M1 mAChR internalized at a rate similar to that of the fast-internalizing receptors, such as transferrin and IgA receptors.
M1 Muscarinic Receptor Rapidly Recycles to the Lateral Membrane
To shed more light on the route of M1 mAChR after endocytosis and to better understand the amount of receptor recycling to the lateral membrane that could not be observed in the presence of agonist, the following experiment was performed. M1 mAChR-expressing cells were treated for 10 min with agonist, and then the agonist was extensively washed out, and the cells were chased for different periods of time. As shown in Figure 4 , within 10 min the M1 mAChR internalized into endosomal compartments. After removal of the agonist, the M1 mAChR receptor rapidly recycled to the lateral membrane. Within the first 10 min, most of the receptor had returned to the lateral PM. The last remains of internalized receptor were observed in endosomal structures 20 min after the removal of agonist; at 30, 40, and 50 min of agonist removal, all of the receptor was observed on the lateral membrane. Thus, the M1 mAChR receptor rap- Figure 2 . The M1 muscarinic receptor is differentially distributed along the lateral membrane and is highly concentrated proximal to the tight junction. MDCK tet-off cells expressing GFP-tagged M1 mAChR were grown for 3 d in Corning transwells and processed for immunofluorescence. Cells were stained for M1 mAChR (GFP, left column) and with anti-E-cadherin (Alexa 594, right column). Sections were taken through the lateral domain every 2 m. M1 mAChR is concentrated proximal to the tight junction and fades with distance. The numbers on the left represent distance in microns from the tight junction toward the basolateral PM. Bar, 5 m. . The M1 muscarinic receptor rapidly recycles back to the lateral membrane. MDCK tet-off cells expressing M1 mAChR-GFP were grown for 3 d in Corning transwells. The cells remained untreated (Control) or were treated with 1 mM carbachol (Carb) for 10 min followed by extensive washes and chasing without carbachol for the indicated times. The cells were then fixed and processed for immunofluorescence and stained for M1 mAChR (GFP). Sections were taken through the lateral domain near the tight junction. Representative images are shown. In the absence of carbachol, M1 mAChR rapidly recycled back to the lateral PM. Bar, 2 m.
idly endocytoses from and rapidly recycles back to the lateral PM.
Mechanism Governing M1 Muscarinic Receptor Endocytosis
To investigate the mechanism by which the M1 mAChR is internalized, we adopted a dominant-negative approach, i.e., expression of mutant forms of polypeptides that are known to participate in and inhibit specific endocytosis pathways. In Figure 5A , it can be seen that expression of dynamin I K44A, a dominant-negative mutant known to inhibit both clathrin-and caveolin-based endocytosis pathways, increased the amount of receptor located at the BL PM to fivefold that of the control cells. This was indicated by an increase in the binding of iodinated anti-HA antibody. Similar expression of the clathrin hub mutant also resulted in a two-to threefold increase in M1 mAChR on the lateral PM. When endocytosis was inhibited by expressing the dominant-negative polypeptides, receptors continued to be delivered to the PM, either from the biosynthetic pathway or by bypassing the inhibitory effect and recycling back to the PM. Under these conditions, receptors accumulated on the PM without being internalized. The fivefold dynamin-dependent and two-to threefold clathrin-dependent M1 mAChR accumulation on the BL PM indicates that endocytosis was severely inhibited by the expression of these constructs. Western blot and incubation of the cells with proteosome inhibitor show that the inhibition of endocytosis inhibits lysosomal degradation of the receptor (Shmuel and Altschuler, unpublished results).
To confirm these observations and to better observe the internalization of the M1 mAChR, the cells were treated with agonist, followed by incubation at 37°C for the indicated time periods. At each time point, the cells were cooled, fixed, and processed for immunofluorescence. Close scrutiny at 0 time ( Figure 5B ; before the addition of agonist) in cells expressing dynamin or clathrin dominant-negative mutants shows the disappearance of internalized M1 mAChR endosomal staining. This observation indicates that the internal staining in the control cells was the result of basal internalization of the receptor rather than of receptor transport via the biosynthetic pathway on its way to the BL membrane. This means that the dominant-negative con- Figure 5 . The M1 muscarinic receptor endocytoses through a dynamin-clathrin-dependent pathway. MDCK tet-off cells expressing HA-tagged M1 mAChR-GFP were grown for 3 d in Corning transwells. Control cells (uninfected) and cells expressing the dominantnegative dynamin I K44A mutant (50 pfu/cell) for 18 h and the dominant-negative clathrin hub mutant (150 pfu/cell) for 24 h were either (A) used to monitor the amount of M1 mAChR accumulating on the PM through binding of 125 I-12CA5 antibody at 4°C to the lateral PM (t test between control and dynamin I K44A and with clathrin hub performed and p value indicated in graph, **p Ͻ 0.01 and *p Ͻ 0.05) or (B) incubated with 1 mM carbachol for 10 or 60 min, or left untreated (control) as indicated, and processed for immunofluorescence. The cells were stained for M1 mAChR (GFP). Sections were taken through the lateral domain in proximity to the tight junction. In A, both dynamin and clathrin mutants are seen to cause a dramatic increase in M1 mAChR on the lateral PM. Images in B show complete inhibition of endocytosis by the dynamin I dominant-negative construct and partial inhibition of endocytosis by the clathrin hub mutant. Arrowheads indicate punctate accumulation of M1 mAChR on the lateral PM. Representative images are shown. Bar, 2 m. (C) Cell expressing the dominant-negative dynamin I K44A as described were not treated or were treated with 1 mM carbachol (Carb) for 5 or 15 min and processed for immunofluorescence. Cells were stained for M1 mAChR (GFP, left column) or with anti-clathrin heavy chain X22 antibody (Alexa 594, right column). Sections were taken through the lateral domain near the tight junction. The dominant-negative dynamin I completely inhibited M1 mAChR endocytosis; clathrin was redistributed and revealed very small punctate staining within minutes of carbachol treatment. Representative images are shown. Bar, 2 m. structs inhibited the basal internalization of M1 mAChR. After 10 min of agonist treatment, the dominant-negative dynamin I-expressing cells showed almost no internalization of M1 mAChR; after 60 min, minimal receptor internalization was observed, with a large amount of receptor decorating the lateral PM. These results indicate that the dominant-negative dynamin construct severely inhibited receptor endocytosis. Cells expressing the dominant-negative clathrin construct showed reduced internalization at both 10 and 60 min. They also showed increased punctate staining at the lateral PM ( Figure 5B, arrowheads) , suggesting accumulation in the clathrin-coated pits.
To more closely observe the distribution of the M1 mAChR in relation to clathrin, dominant-negative dynamin I K44A was coexpressed; this slowed the rate of internalization, enabling us to capture the colocalization of the receptor with clathrin. As seen in Figure 5C , in the absence of agonist, M1 was present mainly on the lateral PM, and clathrin was observed as punctate staining in the cytoplasm. Despite the expression of the dominant-negative dynamin construct, clathrin did not accumulate on the PM. Expression of the dominant-negative dynamin showed that agonist treatment for a period of 5 or 15 min causes redistribution of clathrin to the PM with a significant increase in colocalization with the M1 mAChR at the 15-min time point. These results pinpoint the involvement of the CME pathway in M1 mAChR receptor internalization.
Involvement of Caveolins in M1 Muscarinic Receptor Internalization
Mounting evidence for the involvement of caveolae in GPCR endocytosis (Wyse et al., 2003; Chini and Parenti, 2004; McFarland et al., 2004) , together with our observation that the clathrin dominant-negative construct has a weaker inhibitory effect than the dynamin dominant-negative construct, raises the possibility that caveolae-dependent endocytosis may be involved in the M1 mAChR internalization process. This is in light of the effect of dynamin in caveolae-dependent endocytosis (Nabi and Le, 2003; Shajahan et al., 2004) and the increasing evidence of caveolae involvement in GPCR internalization. To test this hypothesis, we expressed cav 1, cav 2, or cav 1 and 2 together in MDCK cells expressing M1 mAChR for 18 h and assayed M1 mAChR receptor endocytosis. Owing to the elevated sensitivity of MDCK cells to the expression of polypeptides such as caveolins, we used a recombinant adenoviral infection system (Mora et al., 1999) . Infection of MDCK cells with recombinant adenoviruses for cav 1 and 2 for 16 -20 h had no effect on the polarity of the cells, as indicated by the expected localization of several polar markers such as E-cadherin, P58, ZO1, and gp135 (unpublished data). As shown in Figure 6A , expression of cav 1 had no effect on M1 mAChR endocytosis. On the other hand, expression of cav 2 inhibited M1 mAChR endocytosis by as much as 70%. This inhibitory effect was relieved by coexpression with cav 1, suggesting that M1 mAChR associates with cav 2 on the PM, preventing receptor internalization. When both caveolins were expressed, cav 2 preferentially bound cav 1 and released M1 mAChR, enabling its internalization.
Next, we examined the effect of caveolins on the delivery of the M1 mAChR to the lateral PM. M1 mAChR arrives at the lateral PM via the biosynthetic pathway or from recycling endosomes-common endosomes as part of the recycling pathway. In this experiment, radioactive anti-HA antibody was applied to the BL PM, which binds an HA tag placed on the extracellular domain of the receptor. The amount of radioactivity indicates the amount of receptor on the BL PM. Figure 6B shows that expression of cav 1 slightly increased the amount of M1 mAChR on the BL PM. Conversely, expression of cav 2 reduced the amount of M1 mAChR on the surface by as much as 45% compared with the control and by 55% compared with cav 1-expressing cells. Coexpression of both cav 1 and 2 abolished the effects of the caveolins, bringing the amount of surface-localized M1 mAChR to close to control levels. This indicates that the effect achieved mainly by cav 2 is antagonized by cav 1. Both inhibitory effects, on endocytosis and on the presence of M1 mAChR on the BL PM, were manifested upon expression of cav 2 and relieved by expression of cav 1. This raises the possibility of an indirect or direct association between cav 2 and M1 mAChR, which is terminated by the preferential association of cav 1 with cav 2.
The extreme effect on M1 mAChR imposed by the expression of cav 2 and relieved by that of cav 1 suggests that the receptor may be shuttling in and out of DRMs on the PM during the recycling or while in the biosynthetic pathway. To address this possibility, we studied the flotation properties of the M1 mAChR in TX-100 extracts from MDCK cells expressing cav 1, cav 2, or both caveolins. As can be seen in Supplementary Figure 1A , cav 1 was localized in DRM, whereas cav 2 was not. Subsequently ( Supplementary Figure 1B) , the M1 mAChR remained excluded from the DRMs. These results led us to assume that the effect of the caveolins may be mediated in the presence of activated receptor by its agonist. As can be seen in Supplementary Figure 1C , neither agonist treatment nor expression of cav 2 followed by agonist treatment caused the receptor to migrate into the DRMs. Nevertheless, expression of cav 2 along with agonist treatment caused a minor but noticeable shift toward the lighter fractions (fractions 7-10), which are not classical DRMs. These experiments thus rule out the likelihood that the effect of cav 2 on M1 mAChR occurs mainly within the DRM. We hypothesize that cav 2 associates with M1 mAChR along the biosynthetic pathway and on the lateral membrane outside of the DRM. The cav 2-M1 mAChR association competes with cav 1's association with cav 2. When the latter occurs, cav 2 becomes enriched in the DRM, and M1 mAChR is released and free to be endocytosed by the clathrin-mediated machinery.
Newly Synthesized Caveolins 1 and 2 Affect Localization of the M1 Muscarinic Receptor
To further study the effect of caveolins on M1 mAChR trafficking, we first examined the localization of the former in MDCK cells that do not express M1 mAChR. Figure 7A shows that each caveolin, when expressed alone for 16 h, was predominantly localized to the intracellular compartments. When both cav 1 and cav 2 were coexpressed, in addition to their intracellular endosomal localization, they were significantly localized to the lateral PM ( Figure 7A , arrowheads). These results are in agreement with those of previous studies using the adenoviral delivery of caveolins (Parolini et al., 1999) .
To study the effect of caveolin expression on the distribution of M1 mAChR, we infected MDCK cells stably expressing M1 mAChR with adenovirus carrying caveolins under a tet-regulated promoter. As shown in Figure 7B , expression of cav 1 or 2 did not alter the BL localization of the M1 mAChR. On closer inspection, cells expressing cav 2 showed, in addition to the PM localization, intracellular localization of the M1 mAChR. Intracellular M1 mAChR colocalized extensively with cav 2. When both caveolins were expressed, M1 mAChR was localized to intracellular compartments, in addition to its localization in the lateral PM ( Figure 7B, arrowheads) . These results indicate that cav 2, being in the intracellular pathway of the M1 mAChR endocytic pathway, has the potential to affect M1 mAChR trafficking.
To further study M1 mAChR trafficking of agonist-activated receptor, cells expressing M1 mAChR and newly synthesized caveolins were incubated with agonist (1 mM carbachol) for 15 min or for 15 min with a 45-min chase period without agonist. This enabled us to assay the effect of the caveolins on the internalization as well as on the recycling of the receptor back to the lateral PM. A 15-min agonist treatment resulted in complete internalization of the receptor, with none remaining on the lateral PM ( Figure 7C Control) . Figures 3B, 4 , and 5B show that when M1 mAChR was treated with agonist (when caveolins are not coexpressed), a fraction of the receptor decorated the lateral PM. When cav 1 was expressed, no receptor decorated the PM, indicating that in the absence of cav 1, the M1 mAChR rapidly internalizes and a fraction of it (within 15 min of agonist treatment) is recycled to the lateral PM. When caveolins were present, they attenuated receptor transport within the intracellular compartment ( Figure 7C) . A 45-min chase enabled complete recycling of the receptor to the lateral PM ( Figure  4) . In Figure 7D , a fraction of the receptor is seen recycling back to the lateral PM (arrows), whereas the main fraction accumulates in a tight perinuclear compartment, colocalizing with intracellular caveolins. Higher expression of the caveolins resulted in complete cessation of receptor recycling to the PM, whereas a lower level of caveolin expression revealed the appearance of some recycled receptor on the lateral PM. This finding indicates that at a low level of caveolin expression, some receptors elude the interaction with caveolin and recycle back to the lateral PM. On the other hand, at a higher level of caveolin expression, all of the M1 mAChR is associated with caveolins and cannot recycle back to the lateral membrane. These findings support our concept that caveolins attenuate M1 mAChR recycling back to the lateral PM by direct or indirect association.
Intracellular Transport of the M1 Muscarinic Receptor
Our observation that cav 1 and 2 attenuate M1 mAChR either on the BL PM or at intracellular locations motivated us to establish the intracellular pathway of the M1 mAChR and to assay the effect of caveolins on its intracellular transport. Therefore, we focused on one biosynthetic pathway and three endocytic pathways: the epithelial-specific biosynthetic pathway to the BL PM through Rab11-positive endosomes, the recycling pathway starting with arrival at BL early endosomes (Rab5), the degradative-lysosomal pathway through late endosomes (Rab7), and the Rab9-dependent pathway that acts at the late endosomes to rescue membrane proteins back to the TGN (trans-Golgi network). Specifically, we colocalized the M1 mAChR with different endogenous Rab proteins that are well-established markers for the different endosomal compartments in both nonpolarized and polarized epithelial cells Zerial and McBride, 2001; Pfeffer, 2005; Rodriguez-Boulan et al., 2005) . All the antibodies to the different Rab proteins revealed very faint signal in immunofluorescent experiments, and we could not establish colocalization with the different Rab proteins being studied. We therefore transiently expressed Rab proteins fused to red fluorescent protein (RFP). In general, we attempted to express low levels of the Rab proteins in order to minimize their effect on the secretory system where they may cause enlargement of the relevant endosome (Stenmark et al., 1994) . Expression of all Rabs (Rab5, 7, 9, and 11) trapped the M1 mAChR in the corresponding endosomal compartment, even in cells that had not been treated with carbachol. This indicated that a fraction of the M1 mAChR, which is independent of agonist treatment is in transit through the endocytic system, in both the recycling pathway and the degradative pathway.
In Figure 8A we show that in the absence of agonist, a small fraction of the M1 mAChR colocalizes with Rab5 and, interestingly, all Rab5 early endosomes contain M1 mAChR. After a 10-min treatment with the agonist carbachol, all the M1 mAChR are localized to the Rab5 early endosomal compartments; after an additional 20 min of incubation in the presence of the agonist, a significant fraction of the receptor has left the Rab5 early endosomes and appears in other endosomal compartments. In contrast to the complete internalization of the M1 mAChR with 30 min of agonist, in the presence of elevated amounts of Rab5, a small amount of the receptor is recycled back to the PM and retained there. This may be explained by the known inhibitory effect of Rab5 in its GDP state on endocytosis (Stenmark et al., 1994; Barbieri et al., 2000; Galperin and Sorkin, 2003) . Expression of the caveolins did not alter the route or the extent of the M1 mAChR colocalization with Rab5. In addition, cells expressing cav 2 continued to retain the receptor on either the BL PM or in intracellular compartments.
In epithelia, membrane proteins in their biosynthetic pathway and targeted to the basolateral PM may leave the TGN, fuse with the common/recycling endosomes and be targeted to the BL PM or, like E-cadherin, be transported to Rab11-positive endosomes and then delivered to the BL PM (Lock and Stow, 2005) . To address this issue, we colocalized M1 mAChR with Rab11-RFP. In Figure 8B , we show that a fraction of the M1 mAChR colocalizes with Rab11. Expression of cav 1, 2, or both caveolins together with M1 mAChR did not alter the receptor's route or extent of endocytosis. The Rab11 localization may indicate recycling through a Rab11-positive endosome, or that M1 mAChR, in its biosynthetic pathway, arrives at a Rab11-positive endosome after its exit from the TGN.
In epithelial cells, neurons, and nonpolarized cells, Rab7 and Rab9 mark the late endosome compartment. Rab7 spe- cifically marks the late endosome domain that concentrates proteins destined for lysosomal degradation and is involved in late endosome biogenesis (Feng et al., 1995; Kamei et al., 1999; Bucci et al., 2000) . In Figure 8C , M1 mAChR and Rab7 reveal significant colocalization. A closer look at the cells treated with the agonist reveals that many of the intracellular endosomal structures are not labeled with Rab7, indicating that a significant fraction of the M1 mAChR does not utilize the lysosomal degradative pathway. Expression of Rab7 does not alter the effect of cav 2 and its rescue by cav 1. Membrane proteins arriving at the late endosome may escape degradation by sorting to the Rab9-positive domain of the late endosome and being transported to the TGN, from which they can once more be transported to the BL PM. In Figure 8D , cells that have been treated with agonist or left untreated reveal high colocalization between the M1 mAChR and Rab9. Expression of caveolins did not affect the extent of colocalization, as evidenced by analyses of multiple experiments.
These results signify that the M1 mAChR utilizes two recycling pathways: a short pathway through early endosomes and common endosomes and a long pathway through early endosomes, late endosomes, the TGN, and returning to the BL PM (see Figure 11) . The latter pathway enables lysosomal targeting as well as sorting away from the lysosomes of receptors that were misrouted earlier in the pathway.
The M1 Muscarinic Receptor Interacts with Caveolins
The inhibitory effect of cav 2 expression on M1 mAChR endocytosis and its rescue by expression of cav 1 (Figure 6 ), followed by the prominent colocalization of caveolins with M1 mAChR (Figure 7) , led us to examine the interaction between caveolins and the receptor. For this purpose, we adopted an established method for the coimmunoprecipitation of GPCRs and cav 1 (Lu et al., 2001) . MDCK-M1 mAChR expressing cav 1, 2, or both were either not treated or treated with the agonist carbachol for 60 min and processed for coimmunoprecipitation. Western blot analysis of total ly- Cells were then infected with adenovirus for expression of caveolin 1, caveolin 2, or both (50 pfu/cell) for 18 h. Cells were either not treated or treated with carbachol agonist for 10 or 30 min as indicated. The cells were then processed for immunofluorescence. (A-D) Tracing of M1 mAChR (green) and (A) Rab5a (red), (B) Rab11 (red), (C) Rab7 (red), and (D) Rab9 (red). Stimulated and nonstimulated M1 mAChR utilizes both a short recycling pathway (BL early endosome to common endosome) and a long recycling pathway (BL early endosome to late endosomes to TGN and through Rab11-positive endosomes back to the BL PM) and is also delivered to the lysosomes through late endosomes. Representative images are shown. Bar, 2 m.
sates revealed that the expression of caveolins does not alter the amount of monomeric M1 mAChR but increases the amount of oligomeric M1 mAChR, with the highest amount of the latter in cells expressing cav 2. These oligomers are stable to SDS and heat in high-pH sample buffer, similar to the oligomers of cav 1. Treatment of the cells for 60 min with the agonist carbachol resulted in increased oligomerization in control cells but had no effect on the oligomerization of caveolin-expressing cells (Figure 9, A and B) . To assay the interaction of caveolins with M1 mAChR, we immunoprecipitated the latter with anti-HA, which reacts with the HA tag located in the extracellular domain of the receptor. The immunoprecipitate was separated by SDS-PAGE and reacted with cav 1-and cav 2-specific antibodies. The results, shown in Figure 9 , C and D, indicate that independent of agonist treatment, cav 1 in both its monomeric and oligomeric forms interacts with M1 mAChR. Importantly, and independently of M1 mAChR, the cav 1 oligomer is disrupted in the presence of cav 2: the latter completely abolishes the cav 1 oligomer, leaving most of the caveolins as monomers with some homo-dimers (cav 1::cav 1) and some hetero-dimers (cav 1::cav 2; Figure 9 , C and D). Both caveolins instigate the oligomerization of M1 mAChR, whereas the expression of cav 2, which does not oligomerize (like cav 1), stimulates a large amount of M1 mAChR oligomerization. The expression of cav 1 together with cav 2 reduces the amount of M1 mAChR oligomer (compared with oligomer stimulated by cav 2 alone). Most of the M1 mAChR interaction takes place with monomeric cav 2, with some interaction with dimeric cav 2 and heteromeric cav 1::cav 2. We hypothesize that the initial interaction of the M1 mAChR stimulates the oligomerization process to molecular weights similar to those of the caveolin oligomers.
To find out where the caveolin-M1 mAChR interaction takes place-on the PM or in an intracellular compartment, we took advantage of the HA tag positioned in the extracellular domain of the M1 mAChR. We incubated the anti-HA antibody on the BL PM of the cells at 4°C for 60 min, thereby binding the PM fraction of M1 mAChR with the anti-HA antibody. After an extensive wash, we lysed the cells and precipitated the PM fraction of M1 mAChR. The supernatant containing the remainder of the M1 mAChR, consisting mainly of M1 mAChR localized to intracellular compartments, was precipitated by another round of incubation of the unbound cell extract and anti-HA and protein A-Sepharose beads. As shown in Figure 10B (total, right panel), both endogenous and recombinant cav 1 form oligomers, and expression of cav 2 significantly reduces the number of cav 1 oligomers. The interaction with M1 mAChR occurs in intracellular compartments and not on the PM. On the other hand, cav 2 (endogenous and recombinant) interacts with M1 mAChR at both the PM and in intracellular compartments. Interestingly, both cav 1 and 2 are tyrosine phosphorylated when not bound to M1 mAChR. When associated, however, both caveolins are dephosphorylated. These results, together with our observation that cav 2 (but not cav 1) inhibits M1 mAChR endocytosis and that cav 1 abolishes cav 2's inhibition, suggest a scenario in which cav 2 associates with M1 mAChR on the PM and thus inhibits its liganddependent recruitment to the clathrin-coated pit. Cav 1 may associate with cav 2 and thus disrupt cav 2's association with M1 mAChR.
DISCUSSION
In this investigation, we show the involvement of both the clathrin endocytic machinery and caveolins in regulating endocytosis and intracellular transport of the M1 muscarinic receptor.
Endocytosis of the M1 Muscarinic Receptor
We show that M1 mAChR is localized to a restricted subdomain of the lateral PM near the tight junction (Figures 1  and 2 ). On agonist treatment, clathrin is redistributed to the lateral PM ( Figure 5C ), and M1 mAChR endocytosis occurs from this region of the lateral PM ( Figure 3B ). The M1 mAChR internalizes through the clathrin-mediated pathway into the endosomal structures ( Figure 5 ). The internalization rate of the M1 mAChR is similar to that of rapidly internalizing receptors such as transferrin and IgA receptor. Removal of agonist from the media results in rapid recycling of the receptor to the lateral domain, from which it was internalized ( Figure 4) . Further studies showed that expression of cav 2, which localizes mainly to the intracellular compartment and was previously shown to be in the TGN with a minute amount on the lateral membrane, results in the marked reduction of M1 mAChR endocytosis and retention of newly synthesized, as well as internalized receptor in intracellular membranes (Figures 6 and 8 and Mora et al., 1999) . Expression of cav 1 relieves cav 2's inhibitory effect, most likely due to dimerization of cav 1 with cav 2 ( Figure  10 , B and C, total lysates), the former competing with M1 mAChR and enabling the receptor's internalization. Cav 2's association with the M1 mAChR is restricted to non-DRMs, as shown by the absence of both cav 2 and M1 mAChR in the Triton-insoluble fractions of the Nycodenz gradients (Supplemental Figure 1 , B and C) and as supported by the observation that within the Golgi, caveolins are in a monomeric state and detergent-soluble, enabling them to associate with other polypeptides (Pol et al., 2005) .
Differential Localization of M1 Muscarinic Receptor
Most BL-targeted membrane proteins are distributed evenly along the lateral membrane, as shown for E-cadherin ( Figure  2 ). In contrast, the M1 mAChR was highly concentrated proximal to the tight junction and was almost totally absent distal to it (Figure 2) . Several studies have shown that delivery of membrane proteins to the BL PM occurs through a targeting apparatus termed exocyst (Novick et al., 1980) . The exocyst is a 750-kDa, eight-subunit proteinaceous apparatus that regulates the polarized delivery of membrane proteins to the PM. In polarized MDCK epithelial cells, the exocyst (also termed Sec6/8) complex is localized to the lateral membrane near the tight-junction complex (Grindstaff et al., 1998; Lipschutz et al., 2000) , and this region has been shown to be an area of active exocytosis from the common recycling endosome and TGN (Kreitzer et al., 2003) . The mammalian exocyst complex, like its yeast counterpart, is important for specifying exocytic sites leading to localized membrane growth (Matern et al., 2001; Yeaman et al., 2004) . We speculate that the M1 mAChR's restricted localization to this site enables its rapid endo-and exocytosis, similar to the presynaptic neurotransmitter release apparatus, but differs in that the receptor in its resting state is at the PM (Choudhury et al., 2006) .
Caveolin 2 Inhibits Caveolin 1 Oligomers
Cav 1 has been shown to oligomerize into large SDS-insoluble structures. These structures range between 200 and 600 kDa in size, appear in vivo in cell lines that express endogenous cav 1, and are induced by the expression of recombinant cav 1. Cav 1 oligomerization takes place shortly after synthesis and most likely within the TGN, because exit of caveolin is unusually slow relative to other secretory proteins (Ren et al., 2004) . The stability of the SDS-resistant oligomers is dependent on the palmitoylation of three cysteine residues within the C-terminal cytoplasmic tail of cav 1 (Monier et al., 1995 (Monier et al., , 1996 . A large alanine mutation scan performed on cav 1 has shown that of 29 mutated residues, 14 result in aberrant oligomerization and transport out of the TGN (Ren et al., 2004) , indicating that much of the structure of cav 1 is dedicated to the oligomerization that also dictates the exit from the TGN. Cav 2 does not oligomerize independently of cav 1 and does not form SDS-resistant structures. Moreover, mutated cav 1 (cav 1 DGV) retains cav 2 at the Golgi and prevents its oligomerization. Although cav 1 has been shown to draw cav 2 into oligomers that later form increased amounts of caveolae at the BL PM (Lahtinen et al., 2003) , in our system, cav 2 did not oligomerize, even in the presence of cav 1 expression ( Figures 10C and 11C) . Interestingly, we demonstrated that cav 2 completely eliminates the oligomers formed by cav 1. The monitoring of oligomers Figure 10 . On the basolateral plasma membrane, the M1 muscarinic receptor interacts only with caveolin 2. MDCK tet-off cells expressing HA-tagged M1 mAChR-GFP were grown for 3 d on 24-mm transwells and subsequently either not infected (Control) or infected with caveolin 1, caveolin 2, or both (50 pfu/cell of each construct), then incubated for 18 h for expression. The PM fraction of M1 mAChR was then immunoprecipitated by incubating the anti-HA antibody at the BL PM for 60 min at 4°C. Excess antibody was washed, cells were lysed, protein A beads were added, and the receptor was precipitated. Lysate containing intracellular unbound receptor was precipitated with another round of antibody and protein A beads. Immunoprecipitate (left panel) and total lysates (right panel) reacted with either (A) anti-myc identifying recombinant caveolins, (B) specific anti-caveolin 1 identifying endogenous and recombinant caveolin 1, (C) specific anti-caveolin 2 identifying endogenous and recombinant caveolin 2, or (D) anti-phosphotyrosine (4G10) identifying tyrosine-phosphorylated immunoprecipitated proteins. Identified protein complexes are indicated on the right. On the PM, only caveolin 2 interacts with the M1 mAChR, in intracellular compartments both caveolins interact with the receptor, and caveolin 1 interacts in its monomeric and oligomeric forms. Caveolins interacting with M1 mAChR are not tyrosine-phosphorylated. is performed either by following SDS resistance in high-pH sample buffer by boiling or in neutral pH buffer without boiling (Monier et al., 1995) or by sucrose gradients (Lahtinen et al., 2003) . Assuming that the difference between our results, obtained using high-pH sample buffer followed by boiling and those shown by Lahtinen and colleagues are due to the oligomerization-assay methods applied, we conclude that the oligomers formed by both cav 1 and 2 may indicate different biophysical characteristic than those formed by cav 1 alone. This difference in the presence of different lipid contents in the membrane may have effects on the structure and mobility of caveolae.
Clathrin-and Caveolin-mediated Internalization
The biochemical and immunofluorescence data of our study revealed that expression of dominant-negative clathrin heavy chain and dynamin results in inhibition of M1 mAChR endocytosis ( Figure 5) . Moreover, addition of agonist (carbachol) resulted in redistribution of clathrin in cells expressing the M1 mAChR ( Figure 5C ) but had no effect on clathrin in cells that did not express the receptor (unpublished data), promoted the accumulation of M1 mAChR in typical clathrin punctate staining along the lateral PM, and increased the oligomeric form of M1 mAChR (Figure 9 , A and B) and its monoubiquitination (Shmuel and Altschuler, unpublished data). Consequently, we conclude that the M1 mAChR internalizes through a clathrin-mediated pathway independent of agonist treatment. This conclusion is in agreement with previous ones obtained using nonpolarized HEK 293 cells, in which the M1 mAChR revealed dynamin I-dependent internalization (Lee et al., 1998; Vogler et al., 1998) and colocalization with the clathrin and AP2 machinery on the PM (Tolbert and Lameh, 1996) . Because of increasing evidence for caveolae-dependent internalization of GPCRs, including adenosine A1, ␤1 adrenergic, bradykinin B2, and endothelin type A receptors (Chini and Parenti, 2004) , as well as caveolin's interaction with membrane and cytosolic signaling molecules such as Na ϩ /K ϩ -ATPase (Wang et al., 2004) , we tested the possible role of caveolins in M1 mAChR endocytosis. Surprisingly, expression of cav 2 dramatically inhibited endocytosis of the receptor and coexpression of cav 1 and 2 reversed this inhibitory effect ( Figure  6A ). We showed that both caveolins have the capacity to associate with the receptor (Figures 10 and 11) , but on the lateral PM only cav 2 associates with M1 mAChR. Expression of cav 2 stimulated M1 mAChR oligomerization to a higher extent than that of cav 1, but cav 2 itself did not oligomerize ( Figure 9, A and B ). This cav 2 association and receptor oligomerization prevented the receptor's agonistinduced internalization. If cav 2 acts to directly inhibit the endocytic machinery, the amount of receptor localized to the membrane should increase. However, just the opposite occurred: cells expressing cav 2 presented far less receptor on the membrane (Figure 6B ), suggesting that cav 2 also inhibits receptor delivery to the PM within the biosynthetic and recycling pathways (Choudhury et al., 2006) . In Figure 7 , A and B, it can be seen that cav 2 is largely localized to intracellular compartments and is markedly colocalized with the M1 mAChR. As a result, cav 2 expression inhibited endocytosis ( Figure 7C ), as well as recycling (compare Figure 7C with Figure 4) and delivery of the receptor through the biosynthetic pathway ( Figure 7B ). This phenomenon was reversed when cav 1 was coexpressed with cav 2. The intracellular retention by cav 2 and its release is in agreement with previous work that showed cav 2 within the TGN and its transport to the lateral PM in polarized MDCK cells (Mora et al., 1999) . A Nycodenz gradient of Triton-insoluble fractions revealed that the cav 2 association with M1 mAChR occurs outside the DRM and caveolae (Supplemental Figure 1 , B and C). These observations suggest a novel role for cav 2 as a chaperone for membrane proteins, which is regulated by cav 1 outside of the DRMs. The association of cav 1 with cav 2 may compete for the association of cav 2 with the membrane protein or cause its dissociation from the membrane protein. This would enable the receptor to continue in its membrane transport (Figure 7) . The recently described nonacidic cav 1-rich intracellular compartments, termed caveosomes, may be the site in which caveolins Figure 11 . Working model for the caveolindependent trafficking of M1 muscarinic receptor. M1 mAChR in its biosynthetic pathway arrives at the TGN where it is believed to oligomerize in a caveolin-dependent manner. After its exit from the TGN, the receptor arrives at the Rab11-positive common endosome and is delivered to the PM in proximity to the tight junction. A fraction of the M1 mAChR that is concentrated in this area is bound to caveolin 2, most likely in an oligomeric form. In the presence of caveolin 1, however, caveolin 1 associates with caveolin 2, which in turn releases M1 mAChR, enabling the latter's endocytosis through the clathrin-mediated endocytosis machinery. The receptor is delivered to the BL early endosome (Rab5) where it can either recycle back through the "short pathway" and be delivered to the common endosome and then back to the BL PM or take the "long pathway", to be delivered to the late endosome (Rab7 and 9), from which it will utilize the Rab9-dependent pathway and be delivered to the TGN. From the TGN, the receptor will follow a route similar to that of the proteins in the biosynthetic pathway. Alternatively, at the late endosome, the receptor destined for degradation will follow the Rab7 pathway and be delivered to the lysosome. retain the intracellular M1 mAChR. The observations that SV40 traffics through this compartment on its way to the endoplasmic reticulum and that it is retained there for several hours support the notion that caveosomes regulate the kinetics of membrane trafficking by acting as an intermediate station that retains membrane proteins rather than redirecting them to other subcellular compartments (Pelkmans et al., 2001; Tagawa et al., 2005) . Caveosome biogenesis and its behavior in photobleaching experiments as a static structure places it outside the conventional trafficking pathway shown here for M1 mAChR. The lack of M1 mAChR intracellular endosomal structure, which appears in the cells expressing caveolins (Figure 7 ) but seems to be reduced in cells expressing both caveolins and the different Rabs (Figure 8) , may result from the effects of Rab protein expression. We hypothesize that the Rabs redirect the receptor from the caveosome to the conventional membrane-transport pathway. A more attractive site for accumulating M1 mAChR as a monomer and as an oligomer is the TGN, in which cav 1 oligomerizes, and therefore the intracellular site in which M1 mAChR oligomerizes as well. The TGN is also a site common to both the biosynthetic and long recycling pathways of the receptor (Figure 11 ). The caveolin-trapping mechanism that operates both on the PM independent of DRMs, and in intracellular compartments on the M1 mAChR was observed to stimulate the receptor's mono-and polyubiquitination, maintaining a fixed amount of monomeric receptor nonubiquitinated (Shmuel and Altschuler, unpublished data) . This may serve as a novel mechanism to maintain a fixed pool of receptors available for agonist activation. The oligomerized and ubiquitinated pool may later be either degraded or released into the available pool on the lateral PM. This mechanism may be utilized to extend signaling at the PM or inhibit recycling and thus inhibit potential resensitization. Further research is warranted to characterize the intracellular compartment, the mechanism by which cav 2 regulates M1 mAChR transport, and ubiquitination in relation to caveolins. Our observations, together with accumulated findings related to trafficking in epithelia obtained from experiments in MDCK cells (Rodriguez-Boulan et al., 2005) and from recent experiments with caveolins (Pelkmans et al., 2001; Pelkmans and Helenius, 2002; Tagawa et al., 2005) , support a working model in which the M1 mAChR utilizes several routes that maintain a constant amount of available monomeric receptor. This is achieved by caveolin-dependent oligomerization, ubiquitination, and intracellular transport. In summary, M1 mAChR remains near the tight junction and may associate with cav 2. When agonist is applied, the receptor, if not associated with cav 2, internalizes through CME. The release of M1 mAChR from cav 2 on the PM or within intracellular locations may be promoted by the appearance and association of cav 1 with cav 2. The internalized M1 mAChR arrives at the BL early endosome, may be sorted to either a short recycling pathway through the common endosomes, or follow a long recycling pathway through late endosomes, the TGN, common endosomes and back to the BL PM. At the late endosomes, the receptor may either sort to the TGN or to lysosomal degradation. This event is most likely dependent on the ubiquitination state of the receptor (Figure 11 ).
